KR910700050A - Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia - Google Patents

Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia

Info

Publication number
KR910700050A
KR910700050A KR1019900702184A KR900702184A KR910700050A KR 910700050 A KR910700050 A KR 910700050A KR 1019900702184 A KR1019900702184 A KR 1019900702184A KR 900702184 A KR900702184 A KR 900702184A KR 910700050 A KR910700050 A KR 910700050A
Authority
KR
South Korea
Prior art keywords
cooh
iii
formula
compound
ischemia
Prior art date
Application number
KR1019900702184A
Other languages
Korean (ko)
Inventor
엔징어 헬무트
비르케 프란쯔
스트렐러 일제
Original Assignee
디터 라우딘, 루돌프 호프만
베링거 인겔하임 케이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디터 라우딘, 루돌프 호프만, 베링거 인겔하임 케이지 filed Critical 디터 라우딘, 루돌프 호프만
Publication of KR910700050A publication Critical patent/KR910700050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Abstract

내용 없음.No content.

Description

크산틴 옥시다제 억제제로서의 옥소퀴나졸린 유도체의 용 및 그의 허혈증에 대한 용도Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (6)

임의적으로 염의 형태인 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물을 임의로는 염의 형태로 통상적인 부형제 및/또는 담체와 함께 함유함을 특징으로 하는 세포 보호제.A cell protective agent, characterized in that it contains a compound of formula (I), (II), (III) or (IV), optionally in the form of a salt, optionally in the form of a salt, with conventional excipients and / or carriers. 상기 일반식(Ⅰ)에서 치환체 R1,R2,R3및 R4는 (a) COOH/H/H/H, (b) 테트라 졸린 -5-y1/H/H/H, (c) 테트라졸린 -5-y1/H/H/i -프로필 (d) COOH/H/H/i -프로필 (e) 테트라 졸린 -5-y1-NHCO/H/H/i- (f) H/H/H/COOH, (g) CH3/H/H/COOH, (h) CH3O/H/H/COOH, (i) C1/H/H/COOH, (j) Br/H/H/COOH, (k) R1+R2=-CH=CH-CH=CH-/H/COOH, (l) C2H5O/H/H/COOH, (n) CH(CH3)2/H/H/COOH, (o) COOH/H/H/CH3,(p) CH(CH3)2/H/H/ 테트라졸 -5-일을 나타내거나 (q) 완전한 그룹Substituents R 1, R 2, R 3 and R 4 in Formula (I) are (a) COOH / H / H / H, (b) tetrazoline-5-y1 / H / H / H, (c) Tetrazoline-5-y1 / H / H / i-propyl (d) COOH / H / H / i-propyl (e) tetrazoline-5-y1-NHCO / H / H / i- (f) H / H / H / COOH, (g) CH 3 / H / H / COOH, (h) CH 3 O / H / H / COOH, (i) C1 / H / H / COOH, (j) Br / H / H / COOH, (k) R 1 + R 2 = -CH = CH-CH = CH- / H / COOH, (l) C 2 H 5 O / H / H / COOH, (n) CH (CH 3 ) 2 / H / H / COOH, (o) COOH / H / H / CH 3, (p) CH (CH 3 ) 2 / H / H / tetrazol-5-yl or (q) a complete group 나타내고, 상기 일반식(Ⅱ)에서 치환제 R1/R2는 (a) H/H (b) CH(CH3)2/H, (C)CH3/H, (d) C1/H, (e) CH3O/H, (f)CH(CH3)2O/H, (g) C2H5H 또는 (h) 함께 -CH=CH-CH=CH-를 나타내며, 상기 일반식(Ⅲ)에서 치환체 R1/R2는 (a) H/H (b) CH3/H (c) CH(CH3)2/H 또는 (d) H/CH3(e) C2H5/H를 나타내고, 상기 일반식(IV)에서 치환체 R1/R2는 (a) H/H (b) CH3/H 또는 (c) CH(CH3)2/H를 나타낸다.In the above general formula (II), the substituent R 1 / R 2 represents (a) H / H (b) CH (CH 3 ) 2 / H, (C) CH 3 / H, (d) C 1 / H, (e) CH 3 O / H, (f) CH (CH 3 ) 2 O / H, (g) C 2 H 5 H or (h) together represent -CH = CH-CH = CH-, The substituent R 1 / R 2 in (III) is (a) H / H (b) CH 3 / H (c) CH (CH 3 ) 2 / H or (d) H / CH 3 (e) C 2 H 5 / H, and in the general formula (IV), the substituent R 1 / R 2 represents (a) H / H (b) CH 3 / H or (c) CH (CH 3 ) 2 / H. 제1항에 따른 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물을 통상적인 부형제 및/또는 담체와 함께 함유함을 특징으로 하는 허혈후 기관 손상 예방 및 심장 보호제.An agent for preventing and preventing ischemia after ischemia, comprising the compound of formula (I), (II), (III) or (IV) according to claim 1 together with conventional excipients and / or carriers. 세포보호용 약제학적 조성물의 제조를 위한 제1항에 따른 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물의 용도.Use of a compound of formula (I), (II), (III) or (IV) according to claim 1 for the preparation of a pharmaceutical composition for cytoprotection. 세포 독성 효과가 위험 범위까지 관련된 질환, 특히 크산틴옥시다제가 주역할을 하는 질환의 치료 및 예방에 있어서 제1항에 따른 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물의 용도.Of the general formulas (I), (II), (III) or (IV) according to claim 1 in the treatment and prevention of diseases in which Use of the compound. 허혈후 손상 예방 및 심장 보호용 약제학적 조성물의 제조를 위한 제1항에 따른 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물의 용도.Use of a compound of formula (I), (II), (III) or (IV) according to claim 1 for the prevention of post-ischemic injury and for the preparation of a pharmaceutical composition for protection of the heart. 허혈후 손상 예방 및 심장 보호를 위한 제1항에 따른 일반식(Ⅰ), (Ⅱ), (Ⅲ) 또는 (Ⅳ)의 화합물의 용도.Use of a compound of formula (I), (II), (III) or (IV) according to claim 1 for the prevention of post-ischemic injury and for cardiac protection. 참고사항 : 최초출원 내용에 의하여 공개하는 것임.Note: The disclosure is based on the original application.
KR1019900702184A 1989-01-30 1990-01-27 Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia KR910700050A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3902639A DE3902639A1 (en) 1989-01-30 1989-01-30 NEW USE OF HETERO-CONDENSED OXOCHINAZOLE DERIVATIVES
DEP3902639.6 1989-01-30
PCT/EP1990/000152 WO1990008546A1 (en) 1989-01-30 1990-01-27 Oxoquinazoline derivatives used as xanthine oxidase inhibitors and their application in the case of ischemia

Publications (1)

Publication Number Publication Date
KR910700050A true KR910700050A (en) 1991-03-13

Family

ID=6373044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702184A KR910700050A (en) 1989-01-30 1990-01-27 Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia

Country Status (7)

Country Link
KR (1) KR910700050A (en)
AU (1) AU5026390A (en)
CA (1) CA2026318A1 (en)
DE (1) DE3902639A1 (en)
IE (1) IE900317L (en)
IL (1) IL93202A0 (en)
WO (1) WO1990008546A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704203A1 (en) * 1987-02-11 1988-08-25 Boehringer Ingelheim Kg USE OF OXOCHINAZOLINE DERIVATIVES IN THE TREATMENT OF HYPERURICAEMIA

Also Published As

Publication number Publication date
IL93202A0 (en) 1990-11-05
DE3902639A1 (en) 1990-08-02
WO1990008546A1 (en) 1990-08-09
CA2026318A1 (en) 1990-07-31
IE900317L (en) 1990-07-30
AU5026390A (en) 1990-08-24

Similar Documents

Publication Publication Date Title
KR940007022A (en) Piperidine derivatives, their use in the preparation and treatment thereof
KR920012040A (en) Novel Dihydro-Isquinoline Derivatives
ATE6507T1 (en) PIPERIDE INDIVIDUALS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2014545A1 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DK341187D0 (en) VIRUCID AGENT WITH WIDE-SPECIFIC EFFECTS
FR2439187A1 (en) SUBSTITUTED 1-PIPERAZINE-CARBOXAMIDES AND -CARBOTHIOAMIDES DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR930701169A (en) 3-phenyl-5,6-dihydrobenz [C] acridine-7-carboxylic acid and related compounds as immunosuppressive agents
KR910009712A (en) Cefem compound and preparation method thereof
KR880007514A (en) Chinoline compounds
EP0081324A3 (en) Substituted pharmacologically acitve imidazole derivatives and their preparation and use
EP0297303A3 (en) Fluorophores for encapsulation into liposomes
KR900016135A (en) 4-Quinoline Carboxylic Acid Derivatives for the Treatment of Diseases of the Skin and Mucous-Epithelium
KR890009962A (en) Manimicin derivatives, preparation methods and uses thereof
KR930700494A (en) Novel Oxadione Derivatives
KR840007731A (en) Process for preparing cephalosporin compound
KR910700050A (en) Use of oxoquinazolin derivatives as xanthine oxidase inhibitors and their use for ischemia
KR880002518A (en) Anti-inflammatory composition
KR900701763A (en) 1-amino-5-halogenouracil, preparation method thereof, and central nervous system inhibitor containing the compound as an active ingredient
EP0323146A3 (en) Dopamine-beta-hydroxylase inhibitors
KR850000415A (en) Method for preparing quinazolinone derivatives
FR2372145A1 (en)
KR900701273A (en) Anti-Ecstatic Ergoline Derivatives
KR920003970A (en) How to lower blood uric acid content
IE42765L (en) Treatment of circulatory disorders
RU94018525A (en) SUBSTITUTED 2-HYDROXY-3 [1- (1H-IMIDAZOL-4-IL) ALKYL] -BENZOLKARBOXIMIDAMIDES, METHODS OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid